文献速递头颈与中枢神经肿瘤胸部肿瘤

立体定向体部放疗用于仅肺寡转移头颈部鳞状细胞癌:长期临床结局与有利预测因素

Stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Long-term clinical outcome and favorable predictive factors.
PubMed 文献 · Eur J Cancer · 2025-01-27

BACKGROUND: Oligometastatic disease in head and neck squamous cell carcinoma (HNSCC) is a rare setting. Local ablative therapies are the most adopted strategies although no evidence-based recommendations are currently published.…

要点

  • 仅肺寡转移头颈部鳞状细胞癌患者接受立体定向体部放疗后中位至进展时间17个月、总生存46个月。
  • 2年局部控制率为86%。
  • 单因素分析中年龄>70岁患者至进展时间更好(P=0.03)。

核心结论

  • 研究结果提示立体定向体部放疗可能改善经过适当选择的仅肺寡转移头颈部鳞状细胞癌患者的临床结局、延长至进展时间。
  • HPV相关原发头颈部鳞状细胞癌的远处转移灶应检测p16/HPV状态。

研究设计与样本

  • 回顾性评估50例患者(52个转移灶),纳入标准为1-5个肺转移灶,寡转移模式分为新发或诱导性寡进展。
  • 评估至进展时间为立体定向体部放疗最后一天至疾病进展或任何原因死亡的时间,并进行有利临床结局预测因素与生存分析。

主要发现

  • 中位年龄68岁,45例患者ECOG体能状态评分为0-1。
  • 原发肿瘤亚部位为口咽癌者20例,报告HPV阳性状态者13例,大多数患者为新发寡转移模式。
  • 2年局部控制率为86%。
  • 单因素分析中,年龄>70岁患者报告更好的至进展时间(P=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oligometastatic disease in head and neck squamous cell carcinoma (HNSCC) is a rare setting. Local ablative therapies are the most adopted strategies although no evidence-based recommendations are currently published. We report on long-term clinical outcomes of a cohort of HNSCC patients treated with stereotactic body radiotherapy (SBRT) for lung-only oligometastatic disease. MATERIAL AND METHODS: Eligible patients had 1-5 lung metastases. The oligometastatic pattern was classified as "de novo" or "induced oligoprogressive". We evaluated time to progression (TTP) as the time from the last day of SBRT to disease progression or death from any cause. Predictive factors of better clinical outcome and survival analysis were performed. RESULTS: A cohort of 50 patients (52 metastases) was retrospectively evaluated. The median age was 68 years and 45 patients had an ECOG PS 0-1. Oropharynx cancer was the primary tumor subsite in 20 patients and HPV positive status was reported in 13 patients. "De novo" oligometastatic pattern was observed for the majority of patients. After a median follow up of 24,5 months, median TTP and overall survival (OS) from the end of SBRT were 17 months and 46 months, respectively. The 2-years LC rates was 86 %. At univariate analysis, patients aged > 70 years reported a better TTP (0.03). CONCLUSION: Our findings suggested that SBRT may improve clinical outcome prolonging time to progression in a properly selected cohort of HNSCC patients with lung-only oligometastatic disease. Distant metastases from HPV-related primary HNSCC should be tested for p16/HPV status.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Salvestrini V, Bonaparte I, Becherini C, et al. Stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Long-term clinical outcome and favorable predictive factors. Eur J Cancer. 2025. PMID: 39908655. doi:10.1016/j.ejca.2025.115260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。